May 13, 2020 / 10:02 PM / 12 days ago

BRIEF-Helsinn And MEI Pharma Announce Updated Clinical Data From Phase 2 Study Evaluating Pracinostat In Combination With Azacitidine

May 13 (Reuters) - MEI Pharma Inc:

* HELSINN AND MEI PHARMA ANNOUNCE UPDATED CLINICAL DATA FROM THE PHASE 2 STUDY EVALUATING PRACINOSTAT IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGH/VERY-HIGH RISK MYELODYSPLASTIC SYNDROMES

* MEI PHARMA - NEW DATA FROM PHASE 2 STUDY (N=64) DEMONSTRATED ESTIMATED MEDIAN OVERALL SURVIVAL (OS) RATE OF 23.5 MONTHS WITH A 1-YEAR OS RATE OF 77% Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below